Sarasota, FL -- (SBWire) -- 05/16/2018 --Zion Market Research has published a new report titled "Parkinson's Disease Therapeutics Market by Drug Class (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors and Others), by Route of Administration (Oral, Transdermal, Subcutaneous, and Intestinal Infusion) and by Distribution Channel for Hospital Pharmacy, Retail Pharmacy and Online Sales: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2023". According to the report, global parkinson's disease therapeutics market was valued at approximately USD 2.36 billion in 2017 and is expected to generate revenue of around USD 4.31 billion by end of 2023, growing at a CAGR of around 10.6% between 2017 and 2023.
Parkinson's disease is a progressive movement disorder caused when dopamine-producing nerve cells function irregularly. Some of the major symptoms of Parkinson's disease include hand, arms or leg tremors, slow movement, problems associated with balancing and walking and stiff muscles. The fact that this disease is progressive in nature debilitates the patient's condition and the later symptoms of Parkinson's include trouble swallowing, constipation, fixed or blank expressions, dementia and speech disabilities.
Request Free Sample Report @ https://goo.gl/ZWkJgr
According to Parkinson's Foundation based in the U.S., it is estimated that worldwide around 8 to 10 million people are affected by the disease and every year around 70,000 Americans are diagnosed with it. High prevalence and rise in incidence rates of Parkinson's disease in developed countries are driving the growth of the global Parkinson's disease therapeutics market. Also, increase in awareness about Parkinson's disease and high clinical R&D budget by the governments and non-profit organizations are projected to fuel the growth of the Parkinson's therapeutics market during the forecast period. The promising product pipeline represents the potential business development opportunities during the forecast period.
The Parkinson's disease therapeutics market is segmented on the basis of drug type into levodopa combination, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, anticholinergic drugs, catechol-o-methyltransferase (COMT) inhibitors and others. Levodopa combination therapy dominated the global Parkinson's disease therapeutics market, holding a larger share since Levodopa combination therapy is considered a highly effective treatment for controlling the motor symptoms throughout the stages of Parkinson's disease.
Download Research Report Broachers https://goo.gl/r2uVyR
The Parkinson's disease therapeutics market is segmented on the basis of route of administration into the oral, transdermal, subcutaneous, and intestinal infusion. The oral route of administration accounted for the leading share of the global market. Also, the recent launch of Duopa in the U.S. has contributed to a significant share of the intestinal infusion segment in the global market.
Hospital pharmacy, retail pharmacy, and online sales are the major distribution channels of the global Parkinson's disease therapeutics market. The retail pharmacy segment dominated the global Parkinson's disease therapeutics market in 2016 and is likely to gain significant market share by the end of 2023.
North America, Europe, Asia-Pacific, Latin America and Middle East & Africa are key regional segments of global Parkinson's disease therapeutics market. Europe accounted for the largest share of the global Parkinson's disease therapeutics market in 2016, followed by North America. High level of awareness, increase in funding for research and grants, favorable medical reimbursement policies, high prevalence of Parkinson's disease, rapidly growing geriatric population, and promising clinical pipeline products have contributed to the key share of Europe in the Parkinson's disease therapeutics market.
Request For Customization @ https://goo.gl/ee2LZv
Some of the key players in Parkinson's disease therapeutics market include Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., UCB, Inc., STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., Impax Laboratories, Inc., and Others.
This report segments the global Parkinson's disease therapeutics market as follows:
Global Parkinson's Disease Therapeutics Market: Drug Class Segment Analysis
Levodopa Combination
Dopamine Agonists
Monoamine Oxidase B (Mao-B) Inhibitors
Anticholinergic Drugs
Catechol-O-Methyltransferase (Comt) Inhibitors
Others
Global Parkinson's Disease Therapeutics Market: Route of Administration Segment Analysis
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Global Parkinson's Disease Therapeutics Market: Distribution Channel Segment Analysis
Hospital Pharmacy
Retail Pharmacy
Online Sales
Browse Full Report TOC (Table of Contents) here https://goo.gl/Q1m6X2
Global Parkinson's Disease Therapeutics Market: Regional Segment Analysis
North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa
Global Parkinson's Disease Therapeutics Market Set for Rapid Growth, to Reach Value Around USD 4.31 Billion by 2023
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.